Abstract
The β3-adrenergic receptor (β3-AR) has been shown to mediate various pharmacological and physiological effects such as lipolysis, thermogenesis, and relaxation of the urinary bladder. Activation of the β3-AR is thought to be a possible approach for the treatment of obesity, type 2 diabetes mellitus, and frequent urination. Therefore, the β3-AR is recognized as an attractive target for drug discovery. On the other hand, activation of the β1- or β2-AR can cause undesirable side effects such as increased heart rate or muscle tremors. Consequently, a number of recent efforts in this field have been directed toward the design of selective agonists for the β3-AR. This review summarizes recent advances in β3-AR agonists with an emphasis on recent attempts to create potent, selective and orally bioavailable small-molecule agonists.
Keywords: β3-adrenergic receptor, G protein-coupled receptor, agonist, obesity, type2 diabetes mellitus, frequent urination, lipolysis, thermogenesis
Current Medicinal Chemistry
Title: Recent Developments in the Design of Orally Bioavailable β3-Adrenergic Receptor Agonists
Volume: 13 Issue: 1
Author(s): Masaaki Sawa and Hiroshi Harada
Affiliation:
Keywords: β3-adrenergic receptor, G protein-coupled receptor, agonist, obesity, type2 diabetes mellitus, frequent urination, lipolysis, thermogenesis
Abstract: The β3-adrenergic receptor (β3-AR) has been shown to mediate various pharmacological and physiological effects such as lipolysis, thermogenesis, and relaxation of the urinary bladder. Activation of the β3-AR is thought to be a possible approach for the treatment of obesity, type 2 diabetes mellitus, and frequent urination. Therefore, the β3-AR is recognized as an attractive target for drug discovery. On the other hand, activation of the β1- or β2-AR can cause undesirable side effects such as increased heart rate or muscle tremors. Consequently, a number of recent efforts in this field have been directed toward the design of selective agonists for the β3-AR. This review summarizes recent advances in β3-AR agonists with an emphasis on recent attempts to create potent, selective and orally bioavailable small-molecule agonists.
Export Options
About this article
Cite this article as:
Sawa Masaaki and Harada Hiroshi, Recent Developments in the Design of Orally Bioavailable β3-Adrenergic Receptor Agonists, Current Medicinal Chemistry 2006; 13 (1) . https://dx.doi.org/10.2174/092986706775198006
DOI https://dx.doi.org/10.2174/092986706775198006 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Comprehensive Evaluation and Clinical Application of Combined Redox Assay Methods to Determine Total Antioxidant Capacity
Current Analytical Chemistry Adipose Tissue in the Regulation of Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Advances in Treating the Ischaemic Diabetic Foot
Current Vascular Pharmacology Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine Anti-Angiogenesis Drugs in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Stem Cells in Stroke Repair: Current Success & Future Prospects
CNS & Neurological Disorders - Drug Targets Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery Possible Hypoxia Signaling Induced Alteration of Glucose Homeostasis in Rats Exposed to Chronic Intermittent Hypoxia - Role of Antioxidant (Vitamin C) and Ca2+ Channel Blocker (Cilnidipine)
Current Signal Transduction Therapy Editorial:
Current Diabetes Reviews Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology Ambulatory Blood Pressure Monitoring in Prehypertensive Subjects
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic:Supramolecular Devices for the High-Throughput Screening of Drugs,Nutrients and Metabolites in Postgenomic Era (Part 3) (Guest Editor: Grzegorz Bazylak)]
Combinatorial Chemistry & High Throughput Screening The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study
Current Vascular Pharmacology